Researchers from Monash University, collaborating with Seaport Therapeutics, have unveiled a promising new way to deliver medicines orally by harnessing the body’s natural fat-absorption pathways.

The company said the deal signals a clear move from late-stage clinical development toward building the infrastructure required for a potential commercial launch of its lead diagnostic candidate, 64Cu SAR bisPSMA.

BCAL chief executive Shane Ryan described the rollout as an important milestone, highlighting the company’s collaboration with leading pathology providers to accelerate access.

Melbourne-based Amplia Therapeutics, a company focused on developing targeted cancer therapies, has released updated data from its ongoing ACCENT clinical trial. The findings point to outcomes that stand out in a disease long defined by poor prognosis and limited therapeutic breakthroughs.

Celosia Therapeutics has taken a significant step forward in the fight against amyotrophic lateral sclerosis, announcing that the first patient has been dosed in its Phase 1b clinical trial of CTx1000, an experimental genetic medicine targeting a key driver of the disease.

Radiopharm Theranostics (ASX:RAD) has reported encouraging interim results from its ongoing Phase 2b clinical trial of RAD 101, an experimental imaging agent designed to improve the detection of recurrent brain metastases.

Cyclopharm (ASX:CYC) has taken a significant step forward in its United States expansion, securing a multi-site agreement with the University of Pennsylvania Health System, one of the country’s most respected academic healthcare networks.

Emyria (ASX:EMD) has moved a step closer to establishing its first Empax clinic in Victoria, with patient treatments still expected to begin in the second quarter of 2026 as key operational and clinical milestones are achieved.

Orthocell (ASX:OCC) has reported that its Remplir nerve repair device has been used in 23 surgical procedures on Ukrainian soldiers in combat, marking a significant real-world application of the company’s regenerative medicine technology in a conflict setting.

Driving south along Blackburn Road in Clayton, Melbourne, Professor Robyn Ward, Deputy Vice-Chancellor for Research and Enterprise at Monash University and Chair of the Pharmaceutical Benefits Advisory Committee, sees more than an unremarkable stretch of suburban road.

As early bird registration remains open until 27 March, AusMedtech 2026 is steadily coming into view. For many in the sector, it is not just about the formal presentations but also the in-between moments when conversations unfold, and ideas begin to take shape.

Immutep (ASX:IMM) has reported encouraging early progress in developing a first-in-class therapy that could reshape how autoimmune diseases are treated, following completion of a key stage in its first human clinical trial.

In a move that signals growing momentum for Australia’s role in advanced therapeutics, Viral Vector Manufacturing Facility has entered into a licensing agreement with global cell and gene therapy specialist OXB, opening the door to critical viral vector technologies and strengthening the nation’s position in a rapidly expanding field.

AdAlta (ASX:1AD) has moved to strengthen its strategic and market-facing capabilities with the appointment of experienced corporate executive Fadi Diab to its Board as a non-executive director.

Racura Oncology (ASX:RAC) has reached a key clinical milestone with the successful dosing of a patient in Hong Kong, marking both geographic expansion and the completion of the first cohort in its early-stage trial of RC220, a candidate designed to deliver both anticancer activity and cardioprotection.

Australia’s life sciences sector has welcomed a major national push to strengthen research, development and innovation, with industry leaders urging coordinated government action to secure the country’s economic and health future.

Researchers have confirmed that Kappa Myeloma Antigen and Lambda Myeloma Antigen appear on malignant plasma cells but not on healthy ones, opening the door to treatments that could attack cancer cells with far greater precision while sparing the normal immune system.